APPROACHES TO A VACCINE AGAINST HEPATITIS-A - DEVELOPMENT AND MANUFACTURE OF AN INACTIVATED VACCINE

被引:15
作者
ANDRE, FE
机构
[1] SmithKline Beecham Biologicals, Rixensart
关键词
D O I
10.1093/infdis/171.Supplement_1.S33
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The basis for the development of a vaccine against hepatitis A was laid in the 1970s, when virus was replicated in cell culture. Adaptation to growth in cell culture resulted in attenuation and sufficient quantities of virus particles, allowing the development of both live attenuated and inactivated vaccines. Testing of candidate vaccines in volunteers began in the early 1980s, Recently, a formaldehyde-inactivated whole-virion hepatitis A vaccine, the first licensed vaccine against hepatitis A, was introduced in many countries worldwide, and a live attenuated vaccine became available in the People's Republic of China. Other possible avenues for vaccine development include the use of either conventional or recombinant DNA techniques to obtain subunit vaccines, empty capsids, live viral or bacterial vectors, genetic immunization, synthetic peptides, and anti-idiotypes.
引用
收藏
页码:S33 / S39
页数:7
相关论文
共 76 条
[1]   CONTROLLED-RELEASE VACCINES - BIODEGRADABLE POLYLACTIDE POLYGLYCOLIDE (PL/PG) MICROSPHERES AS ANTIGEN VEHICLES [J].
AGUADO, MT ;
LAMBERT, PH .
IMMUNOBIOLOGY, 1992, 184 (2-3) :113-125
[2]   IMMUNE-RESPONSE TO NASAL DELIVERY OF ANTIGENICALLY INTACT TETANUS TOXOID ASSOCIATED WITH POLY(L-LACTIC ACID) MICROSPHERES IN RATS, RABBITS AND GUINEA-PIGS [J].
ALMEIDA, AJ ;
ALPAR, HO ;
BROWN, MRW .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1993, 45 (03) :198-203
[3]  
ANDRE FE, 1990, PROG MED VIROL, V37, P72
[4]   CLINICAL-ASSESSMENT OF THE SAFETY AND EFFICACY OF AN INACTIVATED HEPATITIS-A VACCINE - RATIONALE AND SUMMARY OF FINDINGS [J].
ANDRE, FE ;
DHONDT, E ;
DELEM, A ;
SAFARY, A .
VACCINE, 1992, 10 :S160-S168
[5]   OVERVIEW OF A 5-YEAR CLINICAL-EXPERIENCE WITH A YEAST-DERIVED HEPATITIS-B VACCINE [J].
ANDRE, FE .
VACCINE, 1990, 8 :S74-S78
[6]   NATURAL HOSTS OF HEPATITIS-A VIRUS [J].
BALAYAN, MS .
VACCINE, 1992, 10 :S27-S31
[7]   SAFETY, TOLERABILITY AND IMMUNOGENICITY OF A FORMALIN-INACTIVATED HEPATITIS-A VACCINE (VAQTA(R)) IN RURAL KENTUCKY CHILDREN [J].
BLOCK, SL ;
HEDRICK, JA ;
TYLER, RD ;
SMITH, RA ;
CALANDRA, G ;
PATTERSON, C ;
LEWIS, J ;
SITRIN, R ;
MILLER, W ;
SCHWARTZ, S ;
WIENS, B ;
NALIN, D .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1993, 12 (12) :976-980
[8]   SYNTHESIS AND ASSEMBLY OF HEPATITIS-A VIRUS-SPECIFIC PROTEINS IN BS-C-1 CELLS [J].
BOROVEC, SV ;
ANDERSON, DA .
JOURNAL OF VIROLOGY, 1993, 67 (06) :3095-3102
[9]   CLINICAL-EXPERIENCE WITH AN INACTIVATED HEPATITIS-A VACCINE [J].
CLEMENS, R ;
SAFARY, A ;
HEPBURN, A ;
ROCHE, C ;
STANBURY, WJ ;
ANDRE, FE .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 :S44-S49
[10]   COMPLETE NUCLEOTIDE-SEQUENCE OF AN ATTENUATED HEPATITIS-A VIRUS - COMPARISON WITH WILD-TYPE VIRUS [J].
COHEN, JI ;
ROSENBLUM, B ;
TICEHURST, JR ;
DAEMER, RJ ;
FEINSTONE, SM ;
PURCELL, RH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (08) :2497-2501